Marksans Pharma has received approval by US Food and Drug Administration (USFDA) for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg.
Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are therapeutically equivalent to listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc. Paricalcitol is a Synthetic Vitamin D analog. Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism (overactive para thyroid gland). It has been used to reduce parathyroid hormone level.
Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: